Novel RET agonist for the treatment of experimental neuropathies. (August 2020)

• Record Type: Journal Article
• Authors: Viisanen, Hanna; Nuotio, Ulpukka; Kambur, Oleg; Mahato, Arun Kumar; Jokinen, Viljami; Lilius, Tuomas; Li, Wei; Santos, Hélder A; Karelson, Mati; Rauhala, Pekka; Kalso, Eija; Sidorova, Yulia A
• Is Part Of: Molecular pain. Volume 16(2020)
• Publication Date: 2020-08
• Subjects: Glial cell line-derived neurotrophic factor -- GDNF family ligands -- artemin -- receptor tyrosine kinase RET -- RET agonist -- neuropathy -- spinal nerve ligation -- diabetes mellitus -- neuropathic pain -- diabetic neuropathy; Pain -- Molecular aspects -- Periodicals; Pain -- Pathophysiology -- Periodicals; Pain -- Physiological aspects -- Periodicals; 616.0472
• DOI: 10.1177/1744806920950866
• Languages: English
• ISSNs: 1744-8069

Abstract

The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) alleviate symptoms of experimental neuropathy, protect and stimulate regeneration of sensory neurons in animal models of neuropathic pain, and restore their functional activity. However, clinical development of GFL proteins is complicated by their poor pharmacokinetic properties and multiple effects mediated by several receptors. Previously, we have identified a small molecule that selectively activates the major signal transduction unit of the GFL receptor complex, receptor tyrosine kinase RET, as an alternative to GFLs, for the treatment of neuropathic pain. We then introduced a series of chemical changes to improve the biological activity of these compounds and tested an optimized compound named BT44 in a panel of biological assays. BT44 efficiently and selectively stimulated the GFL receptor RET and activated the intracellular mitogene-activated protein kinase/extracellular signal-regulated kinase pathway in immortalized cells. In cultured sensory neurons, BT44 stimulated neurite outgrowth with an efficacy comparable to that of GFLs. BT44 alleviated mechanical hypersensitivity in surgery- and diabetes-induced rat models of neuropathic pain. In addition, BT44 normalized, to a certain degree, the expression of nociception-related neuronal markers which were altered by spinal nerve ligation, the neuropathy model used in this study. Our results suggest that the GFL mimetic BT44 is a promising new lead for the development of novel disease-modifying agents for the treatment of neuropathy and neuropathic pain.